abrocitinib

Janus kinase 1 inhibitor

Also Known As:

1-Propanesulfonamide, N-(cis-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-; N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide; N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide; PF-04965842

Networked: 119 relevant articles (26 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Valdez, Hernan: 19 articles (05/2022 - 01/2020)
2.	Rojo, Ricardo: 13 articles (08/2022 - 01/2020)
3.	Simpson, Eric L: 12 articles (01/2022 - 01/2020)
4.	Biswas, Pinaki: 10 articles (08/2022 - 01/2020)
5.	DiBonaventura, Marco: 10 articles (08/2022 - 01/2020)
6.	Silverberg, Jonathan I: 10 articles (01/2022 - 01/2020)
7.	Malhotra, Bimal K: 8 articles (09/2022 - 10/2021)
8.	Feeney, Claire: 7 articles (01/2022 - 01/2020)
9.	Wang, Xiaoxing: 5 articles (09/2022 - 01/2022)
10.	Cameron, Michael C: 5 articles (08/2022 - 09/2021)

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema) 03/01/2022 - "A significant improvement in clinical signs was demonstrated with abrocitinib relative to placebo in adolescents with moderate-to-severe atopic dermatitis (AD) in three phase 3, randomized, double-blinded, placebo-controlled studies (JADE TEEN [ClinicalTrials.gov, NCT03796676], JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]). " 01/01/2021 - "In this trial, abrocitinib at a dose of either 200 mg or 100 mg once daily resulted in significantly greater reductions in signs and symptoms of moderate-to-severe atopic dermatitis than placebo at weeks 12 and 16. " 03/01/2022 - "In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. " 08/01/2022 - "Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life." 09/01/2022 - "Multiple clinical trials showed that 12 weeks of abrocitinib monotherapy was safe and effective for the treatment of moderate-to-severe atopic dermatitis (AD). "
2.	Pruritus (Itching) 10/01/2023 - "In patients with moderate-to-severe AD, long-term abrocitinib treatment resulted in clinically meaningful skin and pruritus improvement. " 01/01/2023 - "Before abrocitinib treatment, the visual analog scale (VAS) score was 10, the 12-item pruritus severity scale (12-PSS) score was 19, and the dermatology life quality index (DLQI) score was 18. " 01/01/2023 - "Abrocitinib can quickly relieve itching within 24 hours. " 01/01/2023 - "In addition, abrocitinib could rapidly relieve itching, and effectively improve symptoms and signs, with a greater effect at the dosage of 200 mg than 100 mg." 01/01/2023 - "After 1 month of oral administration of abrocitinib, the skin lesions gradually subsided, pruritus was relieved, and no adverse side effects occurred. "
3.	Eczema 03/01/2022 - "Abrocitinib 200 mg and 100 mg significantly improved the extent and severity of AD as assessed by a measure called the Eczema Area and Severity Index (EASI) compared to placebo at week 2. Improvements were maintained for up to 16 weeks. " 12/01/2023 - "From the abrocitinib 200-mg, 100-mg, and placebo arms, respectively, Eczema Area and Severity Index response was recaptured by 28.6%, 25.0%, and 52.9% of adolescents and 34.3%, 33.7%, and 58.0% of adults; Investigator's Global Assessment response, by 42.9%, 50.0%, and 73.5% of adolescents and 34.3%, 50.6%, and 74.1% of adults. " 03/01/2022 - "At week 12, more adolescents treated with abrocitinib (200 or 100 mg) vs. placebo achieved a ≥ 4-point improvement from baseline in the Patient-Oriented Eczema Measure in JADE TEEN (83.9% and 77.0% vs. 60.2%) and JADE MONO-1/-2 (83.0% and 69.4% vs. 43.5%) and a ≥ 6-point improvement from baseline in the Children's Dermatology Life Quality Index in JADE TEEN (73.8% and 67.5% vs. 56.5%) and JADE MONO-1/-2 (70.0% and 57.1% vs. 19.0%). " 01/01/2022 - "Among patients with flare in the abrocitinib 200 mg, abrocitinib 100 mg, and placebo groups, 36.6%, 58.8%, and 81.6% regained investigator global assessment 0/1 response, respectively, and 55.0%, 74.5%, and 91.8% regained eczema area and severity index response, respectively, with rescue treatment. During maintenance, 63.2% and 54.0% of patients receiving abrocitinib 200 and 100 mg, respectively, experienced adverse events. " 12/01/2019 - "Reductions in the Eczema Area and Severity Index were 82.6% (90% CI, 72.4%-92.8%; P < .001) for those receiving 200 mg of abrocitinib, 59.0% (90% CI, 48.8%-69.3%; P = .009) for those receiving 100 mg of abrocitinib, and 35.2% (90% CI, 24.4%-46.1%) for those receiving placebo. "
4.	Skin Diseases (Skin Disease) 01/01/2022 - "Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-to-severe atopic dermatitis, a common immunoinflammatory skin disease. "
5.	Nausea 12/01/2023 - "Abrocitinib had a similar safety profile regardless of age; nausea incidence was higher in adolescents. " 10/01/2021 - "Adverse events were reported for 59 (62.8%), 54 (56.8%), and 50 (52.1%) patients in the 200 mg, 100 mg, and placebo groups, respectively; nausea was more common with abrocitinib, 200 mg (17 [18.1%]) and 100 mg (7 [7.4%]). " 01/01/2021 - "However, the analysis favored the efficacy of abrocitinib 200 mg over 100 mg, but side effects such as nausea and headache are likely to occur more with 200 mg." 01/01/2021 - "Nausea occurred in 11.1% of the patients in the 200-mg abrocitinib group and 4.2% of those in the 100-mg abrocitinib group, and acne occurred in 6.6% and 2.9%, respectively. " 01/01/2022 - "Most common adverse events among abrocitinib-treated patients were nasopharyngitis, nausea, acne, and headache. "

Related Drugs and Biologics

1.	dupilumab
2.	upadacitinib
3.	Janus Kinase 1
4.	Janus Kinases
5.	Cyclosporine (Ciclosporin)
6.	lebrikizumab
7.	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)
8.	Janus Kinase Inhibitors
9.	Proteins (Proteins, Gene)
10.	Organic Cation Transporter 1

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Retreatment
4.	Aftercare (After-Treatment)
5.	Immunotherapy